Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction

Archives of Internal Medicine

Volumn 156, Issue 14, 1996, Pages 1506-1510

  Eisenberg, Mark J ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ACUTE HEART INFARCTION; BLEEDING; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANIMALS; ASPIRIN; CLINICAL TRIALS; HOSPITALIZATION; HUMANS; MYOCARDIAL INFARCTION; RECURRENCE; TIME FACTORS;

EID: 0030056053     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.14.1506     Document Type: Review

References (34)

1. Resnekov L, Chediak S, Hirsh J, Lewis HD Jr. Antithrombotic agents in coronary artery disease. Chest. 1989;95(suppl):52S-72S.
2. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl JAtef. 1980:303:897-902.
3. DeWood MA, Slitter WF, Simpson CS, et al. Coronary artériographie findings soon after non-Qwave myocardial infarction. NEnglJMed. 1986; 315:417-423.
4. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol. 1992;19:671-677.
5. Sherry S, Marder VJ. Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy. J Am Coll Cardiol. 1992:19:678-680.
6. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction. N Engl J Med. 1987:317:1055-1059.
7. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness, and side effects. Chest. 1992;102(suppl):327S-336S.
8. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993:87:659-675.
9. Patrono C. Aspirin as an antiplatelet drug. W Engt J Med. 1994;330:1287-1294.
10. Cerskus AL, All M, Davies BJ, McDonald JWD. Possible significance of small numbers of functional platelets in a population of aspirin-treated platelets in vitro and in vivo. Thromb Res. 1980; 18:389-397.
11. O'Brien JR. Effects of salicylates on human platelets. Lancet. 1968:1:779-783.
12. Coller ES. Platelets and thrombolytic therapy. N Engl J Med. 1990:322:33-42.
13. Basinski A, Naylor CD. Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy. J Clin Epidemiol. 1991;44: 1085-1096.
14. Fitzgerald DJ, Catella F, Roy L, Fitzgerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation. 1988;77:142-150.
15. Collen D, Topol EJ, Tiefenbrunn AJ, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984:70:1012-1017.
16. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154.
17. Weksler BB, Tack-Goldman K, Subramanian VA, Gay WA Jr. Cumulative inhibitory effect of lowdose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation. 1985:71:332-340.
18. Kyrie PA, Eichler HG, Jager U, Lechner K. Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo. Circulation. 1987;75: 1025-1029.
19. De Caterina R, Giannessi D, Boem A, et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost. 1985;54:528-532.
20. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevenx -tion of cardiovascular disease. Circulation. 1989:80:749-756.
21. Willard JE, Lange RA, Hiliis LD. The use of aspirin in ischémie heart disease. NEnglJMed. 1992:327:175-181.
22. Jafri SM, Zarowitz B, Goldstein S, Lesen M. The role of antiplatelet therapy in acute coronary syndromes and for secondary prevention following a myocardial infarction. Prog Cardiovasc Dis. 1993; 36:75-83.
23. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. NEnglJMed. 1983:309:396-403.
24. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. H Engl J Med. 1985:313:1369-1375.
25. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
26. The RISC Group. Risk of myocardial infarction and death during treatment with low dose asph rin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990; 336:827-830.
27. Elwood PC, Williams WO. A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. J R Coll Gen Pract. 1979:29:413-416.
28. ISIS (International Studies of Infarct Survival) Pilot Study Investigators. Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J. 1987;8:634-642.
29. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both,- or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2: 349-360.
30. Rawles JM, Haites NE. Patient and general practitioner delays in acute myocardial infarction. BMJ. 1988:296:882-884.
31. Weaver WD, Eisenberg MS, Martin JS, et al. Myocardial infarction triage and intervention project, phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. JAm Coll Cardiol. 1990:15:925-931.
32. Wilcox RG, Olsson CG, Skene AM, Von Der Lippe G, Jensen G, Hampton JR, for the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988:2:525-530.
33. Kamp TJ, Goldschmidt-Clermont PJ, Brinker JA, Resar JR. Myocardial infarction, aortic dissection, and thrombolytic therapy. Am Heart J. 1994; 128:1234-1237.
34. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissuetype plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988:77:670-677.